These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 37963821)

  • 1. A Versatile Platform to Generate Prodrugs with Rapid and Precise Albumin Hitchhiking and High Cargo Loading for Tumor-Targeted Chemotherapy.
    Li J; Xing H; Chen J; Lu H; Tao Z; Tao Y; Sun Y; Su T; Li X; Chang H; Chen S; Chen Z; Yang H; Cheng J; Zhu H; Lu X
    Small; 2024 Mar; 20(13):e2304253. PubMed ID: 37963821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fusion to an albumin-binding domain with a high affinity for albumin extends the circulatory half-life and enhances the in vivo antitumor effects of human TRAIL.
    Li R; Yang H; Jia D; Nie Q; Cai H; Fan Q; Wan L; Li L; Lu X
    J Control Release; 2016 Apr; 228():96-106. PubMed ID: 26951928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homogeneous tumor targeting with a single dose of HER2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remission in mice.
    Xenaki KT; Dorrestijn B; Muns JA; Adamzek K; Doulkeridou S; Houthoff H; Oliveira S; van Bergen En Henegouwen PM
    Theranostics; 2021; 11(11):5525-5538. PubMed ID: 33859761
    [No Abstract]   [Full Text] [Related]  

  • 4. Maleimide-oligo(ethylene glycol) derivatives of camptothecin as albumin-binding prodrugs: synthesis and antitumor efficacy.
    Warnecke A; Kratz F
    Bioconjug Chem; 2003; 14(2):377-87. PubMed ID: 12643748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maleimide-functionalised platinum(IV) complexes as a synthetic platform for targeted drug delivery.
    Pichler V; Mayr J; Heffeter P; Dömötör O; Enyedy ÉA; Hermann G; Groza D; Köllensperger G; Galanksi M; Berger W; Keppler BK; Kowol CR
    Chem Commun (Camb); 2013 Mar; 49(22):2249-2251. PubMed ID: 23396381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytosine arabinoside prodrug designed to bind plasma serum albumin for drug delivery.
    Wei W; He Z; Yang J; Sun M; Sun J
    Drug Deliv Transl Res; 2018 Oct; 8(5):1162-1170. PubMed ID: 29748833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Precisely albumin-hitchhiking tumor cell-activated reduction/oxidation-responsive docetaxel prodrugs for the hyperselective treatment of breast cancer.
    Wei W; Luo C; Yang J; Sun B; Zhao D; Liu Y; Wang Y; Yang W; Kan Q; Sun J; He Z
    J Control Release; 2018 Sep; 285():187-199. PubMed ID: 30017721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Customizing a Tridomain TRAIL Variant to Achieve Active Tumor Homing and Endogenous Albumin-Controlled Release of the Molecular Machine In Vivo.
    Tao Z; Liu Y; Yang H; Feng Y; Li H; Shi Q; Li S; Cheng J; Lu X
    Biomacromolecules; 2020 Oct; 21(10):4017-4029. PubMed ID: 32804484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel auristatin E-based albumin-binding prodrugs with superior anticancer efficacy in vivo compared to the parent compound.
    Pes L; Koester SD; Magnusson JP; Chercheja S; Medda F; Abu Ajaj K; Rognan D; Daum S; Nollmann FI; Garcia Fernandez J; Perez Galan P; Walter HK; Warnecke A; Kratz F
    J Control Release; 2019 Feb; 296():81-92. PubMed ID: 30639692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Comparative Study on Albumin-Binding Molecules for Targeted Tumor Delivery through Covalent and Noncovalent Approach.
    Um W; Park J; Youn A; Cho H; Lim S; Lee JW; Yoon HY; Lim DK; Park JH; Kim K
    Bioconjug Chem; 2019 Dec; 30(12):3107-3118. PubMed ID: 31756089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extending Half Life of H-Ferritin Nanoparticle by Fusing Albumin Binding Domain for Doxorubicin Encapsulation.
    Wang C; Zhang C; Li Z; Yin S; Wang Q; Guo F; Zhang Y; Yu R; Liu Y; Su Z
    Biomacromolecules; 2018 Mar; 19(3):773-781. PubMed ID: 29328653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endogenous IgG-based affinity-controlled release of TRAIL exerts superior antitumor effects.
    Yang H; Feng Y; Cai H; Jia D; Li H; Tao Z; Zhong Y; Li Z; Shi Q; Wan L; Li L; Lu X
    Theranostics; 2018; 8(9):2459-2476. PubMed ID: 29721092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tandem fusion of albumin-binding domains promoted soluble expression and stability of recombinant trichosanthin in vitro and in vivo.
    Ren Z; Zhao J; Cao X; Wang F
    Protein Expr Purif; 2022 Dec; 200():106147. PubMed ID: 35917982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2-fluoro-5-maleimidobenzoic acid-linked albumin drug (MAD) delivery for selective systemic targeting of metastatic prostate cancer.
    Akinboye ES; Rogers OC; Isaacs JT
    Prostate; 2018 Jun; 78(9):655-663. PubMed ID: 29572902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancing the circulating half-life and the antitumor effects of a tumor-selective cytotoxic peptide by exploiting endogenous serum albumin as a drug carrier.
    Su T; Yang H; Fan Q; Jia D; Tao Z; Wan L; Lu X
    Int J Pharm; 2016 Feb; 499(1-2):195-204. PubMed ID: 26752086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetically-engineered protein prodrug-like nanoconjugates for tumor-targeting biomimetic delivery via a SHEATH strategy.
    Chang Y; Yao S; Chen Y; Huang J; Wu A; Zhang M; Xu F; Li F; Huang Y
    Nanoscale; 2019 Jan; 11(2):611-621. PubMed ID: 30556550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conjugating aldoxorubicin to supramolecular organic frameworks: polymeric prodrugs with enhanced therapeutic efficacy and safety.
    Liu YY; Wang ZK; Yu SB; Liu Y; Wang H; Zhou W; Li ZT; Zhang DW
    J Mater Chem B; 2022 Jun; 10(22):4163-4171. PubMed ID: 35551323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Albumin nanoscience: homing nanotechnology enabling targeted drug delivery and therapy.
    Lamichhane S; Lee S
    Arch Pharm Res; 2020 Jan; 43(1):118-133. PubMed ID: 31916145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of affinity and valency of an albumin-binding domain (ABD) on the half-life of a single-chain diabody-ABD fusion protein.
    Hopp J; Hornig N; Zettlitz KA; Schwarz A; Fuss N; Müller D; Kontermann RE
    Protein Eng Des Sel; 2010 Nov; 23(11):827-34. PubMed ID: 20817756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-Activity Relationships of Triple-Action Platinum(IV) Prodrugs with Albumin-Binding Properties and Immunomodulating Ligands.
    Fronik P; Poetsch I; Kastner A; Mendrina T; Hager S; Hohenwallner K; Schueffl H; Herndler-Brandstetter D; Koellensperger G; Rampler E; Kopecka J; Riganti C; Berger W; Keppler BK; Heffeter P; Kowol CR
    J Med Chem; 2021 Aug; 64(16):12132-12151. PubMed ID: 34403254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.